Antibodies targeting PD-L1 and PD-1 have been approved to treat solid and hematological malignancies, including melanoma, bladder cancer, head and neck cancer, RCC, NSCLC, HCC, and other tumors. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.